BLRX - BioLineRx: A Top Candidate For A Takeover Before 2022 Ends

• On May 4, the company crossed successfully a crucial hurdle, putting it en-route toward getting an FDA approval as early as next year.
• As is the case with all micro-cap biotechs, investors remain skeptical due to the expected cash burn until, surely after, a possible approval.
• Not only does BioLineRx has sufficient liquidity for the next two years, but there are additional catalysts along the next 18 months.
• We believe that BLRX has a good chance to be bought out for a stock price in the mid-high teens, possibly before 2022 comes to an end.

For further details see: